Analysis of Coagulation Parameters in Patients with Breast Pathology and Their Possible Relevance to a Hypercoagulable State

Ganesan, Nidhya; Mariano, Stefan; Chitra, R; Kumar, Prasanna N

doi:10.61186/ijbc.16.4.47

Volume 16, Issue 4 (December 2024 2024) Iranian Journal of Blood and Cancer 2024, 16(4): 47-55 | Back to browse issues page

‎ 10.61186/ijbc.16.4.47

Mendeley

Zotero

RefWorks

Ganesan N, Mariano S, Chitra R, Kumar P N. Analysis of Coagulation Parameters in Patients with Breast Pathology and Their Possible Relevance to a Hypercoagulable State. Iranian Journal of Blood and Cancer 2024; 16 (4) :47-55
URL: http://ijbc.ir/article-1-1649-en.html

Analysis of Coagulation Parameters in Patients with Breast Pathology and Their Possible Relevance to a Hypercoagulable State

Nidhya Ganesan ^*¹

, Stefan Mariano²

, R Chitra³

, Prasanna N Kumar²

1- Department of Pathology, PSG Institute of Medical Sciences and Research, Off, Avinashi Rd, Peelamedu, Coimbatore, Tamil Nadu 641004. , nidhyaganesan@yahoo.com
2- Department of Pathology, PSG Institute of Medical Sciences and Research, Off, Avinashi Rd, Peelamedu, Coimbatore, Tamil Nadu 641004.
3- Department of Surgery, PSG Institute of Medical Sciences & Research, Avinashi Rd, Peelamedu, Coimbatore, Tamil Nadu 641004.

Abstract: (438 Views)

Background: To study the alteration in coagulation parameters such as activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), D-dimer and fibrinogen among patients with benign and malignant breast lesions when compared to normal controls.
Materials and methods: The present study was a prospective cross-sectional study conducted among 50 cases diagnosed with benign and malignant breast cancer and comparing them with 20 age-matched controls. Coagulation parameters such as PT, TT, APTT, fibrinogen, and D-dimer were collected and compared between the malignant cases, benign cases, and age-matched control groups based on clinical and demographic details, the status of Progesterone receptor, Estrogen receptor, Her2 Neu, side and grading of cancer.
Results: Significant difference was reported with regard to mean age (p=0.0103) between malignant and benign tumor group (p=0.0103). Mean fibrinogen (p<0.001), thrombin time (p=0.007), and D-dimer (p<0.001) between the three groups also showed a statistically significant difference.
Conclusion: Of the biological parameters assessed in the present study; thrombin time, D-dimer and fibrinogen levels show significant differences in patients with benign and malignant breast diseases. This may serve as a biological marker to evaluate the beginning of Cancer-associated venous thrombosis (CAT) in breast cancer patients.

Keywords: Biomarkers, Blood coagulation, Breast neoplasm, Fibrin fragments, Thrombosis

Full-Text [PDF 541 kb] (157 Downloads)

: Original Article | Subject: Adults Hematology & Oncology
Received: 2024/11/7 | Accepted: 2024/12/3 | Published: 2024/12/30

References

1. Kyriazi V. Breast cancer as an acquired thrombophilic state. J Breast Cancer. 2012 Jun;15(2):148-56. [DOI:10.4048/jbc.2012.15.2.148]

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021 May;71:209-49. [DOI:10.3322/caac.21660]

3. Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020 Aug;8(8):e1027-37. [DOI:10.1016/S2214-109X(20)30215-1]

4. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Dec; 66:15-23. [DOI:10.1016/j.breast.2022.08.010]

5. Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: Result from National Cancer Registry Programme, India. Indian J Med Res. 2022 Oct-Nov;156(4&5):598-607. [DOI:10.4103/ijmr.ijmr_1821_22]

6. Beinse G, Berger F, Cottu P, Dujaric ME, Kriegel I, Guilhaume MN, et al. Circulating tumor cell count and thrombosis in metastatic breast cancer. J Thromb Haemost. 2017 Oct;15(10):1981-1988. [DOI:10.1111/jth.13792]

7. Rückerl R, Schneider A, Hampel R, Breitner S, Cyrys J, Kraus U, et al. Association of novel metrics of particulate matter with vascular markers of inflammation and coagulation in susceptible populations -results from a panel study. Environ Res. 2016 Oct; 150:337-347. [DOI:10.1016/j.envres.2016.05.037]

8. Campello E, Spiezia L, Radu CM, Simioni P. Microparticles as biomarkers of venous thromboembolic events. Biomark Med. 2016 Jul;10(7):743-55. [DOI:10.2217/bmm-2015-0063]

9. Snoderly HT, Boone BA, Bennewitz MF. Neutrophil extracellular traps in breast cancer and beyond: current perspectives on NET stimuli, thrombosis and metastasis, and clinical utility for diagnosis and treatment. Breast Cancer Res. 2019 Dec;21(1):145. [DOI:10.1186/s13058-019-1237-6]

10. Madhav MR, Nayagam SG, Biyani K, Pandey V, Kamal DG, Sabarimurugan S, et al. Epidemiologic analysis of breast cancer incidence, prevalence, and mortality in India: Protocol for a systematic review and meta-analyses. Medicine (Baltimore). 2018 Dec;97(52):e13680. [DOI:10.1097/MD.0000000000013680]

11. Gochhait S, Sahoo SS, Chhabra G, Mukhopahay AK, Sharma S. Role of D-dimer in patients of operable breast cancer withlymph node metastases: A matched cross-sectional study. Oncol J India. 2020 May-Aug;4(2):39-42. [DOI:10.4103/oji.oji_16_20]

12. Okello CD, Mulumba Y, Omoding A, Ddungu H, Orem J. Survival of patients with cancer associated thrombosis at the Uganda Cancer Institute. Ecancermedicalscience. 2021 Mar; 15:1212. [DOI:10.3332/ecancer.2021.1212]

13. Kovac M, Kovac Z, Tomasevic Z, Tomic B, Gvozdenov M, Radojkovic D. Breast cancer and recurrent thrombosis - Results from prospective single center study. Breast J. 2019 Jul;25(4):783-785. [DOI:10.1111/tbj.13326]

14. Wang L, Wang J, Li P, Wang X, Wu S, Shi B. Association between short-term heart rate variability and blood coagulation in patients with breast cancer. Sci Rep. 2021 Jul;11(1):15414. [DOI:10.1038/s41598-021-94931-w]

15. Pang M, Zhao F, Yu P, Zhang X, Xiao H, Qiang W, et al. The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer. Gland Surg. 2021 Apr;10(4):1439-1446. [DOI:10.21037/gs-21-117]

16. Hill CN, Hernández-Cáceres MP, Asencio C, Torres B, Solis B, Owen GI. Deciphering the Role of the Coagulation Cascade and Autophagy in Cancer-Related Thrombosis and Metastasis. Front Oncol. 2020 Dec;10:605314. [DOI:10.3389/fonc.2020.605314]

17. Mandoj C, Pizzuti L, Sergi D, Sperduti I, Mazzotta M, Lauro LD, et al. Observational study of coagulation activation in early breast cancer: Development of a prognostic model based on data from the real-world setting. J Transl Med. 2018 May;16(1):129. [DOI:10.1186/s12967-018-1511-x]

18. Dirix LY, Oeyen S, Buys A, Liégois V, Prové A, Van De Mooter T, et al. Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer. Breast Cancer Res Treat. 2022 Apr;192(3):583-591. [DOI:10.1007/s10549-021-06484-1]

19. Mi XK, Liu QR, Zhu L, Sang MX, Guo LR, Shan BE. Mechanism of the high coagulation state of breast cancer tissue factor. Eur Rev Med Pharmacol Sci. 2017 May;21(9):2167-2171.

20. Khan UT, Walker AJ, Baig S, Card TR, Kirwan CC, Grainge MJ. Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis. BMC Cancer. 2017 Nov;17(1):747. [DOI:10.1186/s12885-017-3719-1]

Send email to the article author

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb